FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
Journal title abbreviation:
J Clin Oncol
Year:
2020
Journal volume:
38 Suppl S
Journal issue:
15
Print-ISSN:
0732-183X
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)